News | January 31, 2022
Granules Pharmaceuticals concludes USFDA audit with three minor observations
The audit is a PAI for two of its product applications filed from this facility
The audit is a PAI for two of its product applications filed from this facility
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
Torrent Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.
The company has 47 ANDA's pending approval with the U.S.FDA
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
It is the generic version of molnupiravir
It will be marketed under the brand name Molunamax
The cash consideration for the acquisition is US$ 18 million.
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
Subscribe To Our Newsletter & Stay Updated
